Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development

PROJECT ABSTRACT Xylyx is developing a pulmonary fibrosis disease modeling and anti-fibrotic compound testing platform aimed at improving the physiological relevance and predictive value of in-vitro models for idiopathic pulmonary fibrosis (IPF) to power the investigation of IPF disease biology and accelerate development of drugs to treat IPF.

Devastating, intractable, and life-threatening, IPF is an interstitial lung disease characterized by obliteration of pulmonary alveoli and progressive loss of respiratory function. Over 55,000 new cases of IPF are diagnosed each year. Median survival is 3–4-years, and annual mortality in the US exceeds 40,000. The etiology and

pathogenesis of IPF remain unknown. Predictive animal and in-vitro models of IPF for basic science research and drug development are severely lacking, leaving a significant unmet need and market opportunity for a physiologically-relevant in-vitro platform that enables high-fidelity cell-based phenotypic studies of IPF. This

SBIR Fast Track will support development and validation studies for commercialization of an IPF disease modeling and compound testing platform that recapitulates in vitro key features of the human IPF disease environment and has been shown to support fibrotic phenotype of human lung fibroblasts to improve cell-based

assays in early-stage anti-fibrotic drug discovery. The technological innovation is the product’s human IPF fibrotic lung specificity stemming from proprietary methods for isolating acellular human IPF lung extracellular matrix (ECM) with the composition and biomechanics of human IPF lung tissue. Our ‘physiomimetic approach’ yields

standardized human fibrotic lung cell culture substrates for predictive in-vitro models of IPF that enable more physiologic and thus more predictive studies, providing a major competitive advantage over existing products like collagen-coated polystyrene plates. The goal is validation and commercialization of standard human IPF

lung ECM disease modeling and compound testing platform for predictive in-vitro models of IPF to greatly reduce dependence on animal models and enable more relevant results for IPF drug developers. Specific aims are to: (i) determine transcriptomic and metabolomic profiles of lung fibroblasts in human IPF and normal lung ECM

hydrogels, (ii) evaluate quality and consistency of human IPF and normal lung ECM hydrogels, (iii) perform compound testing studies with IPF standard-of-care drugs. After successful completion of the Fast Track project, Xylyx will commercialize the IPF compound testing platform to scientists in pharmaceutical companies in need

of predictive IPF disease models for drug discovery and screening, thus reducing the significant costs associated with late-stage attrition due to poor efficacy, and facilitating the development of improved treatment options for the more than 3 million sufferers of IPF worldwide. The product of this SBIR Fast Track will immediately enter

the rapidly growing cell culture market segment in biopharma and drug development, valued at USD $6.4B in 2014 and estimated to reach USD $29.2B by 2024, and will support drug development aimed at the USD $3.0B IPF treatment market.